Trials / Unknown
UnknownNCT05409417
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection rate and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Experimental drug | Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-02-01
- Completion
- 2024-09-01
- First posted
- 2022-06-08
- Last updated
- 2022-06-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05409417. Inclusion in this directory is not an endorsement.